Olaparib has demonstrated single agent activity in breast and ovarian cancer patients with BRCA1/2 germline mutations [34, 35], with over 40% response rate reported in patients with BRCA1-mutant ovarian cancer [34]. Here, BRCA1 is linked to ovarian carcinoma.